[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade",
    "summary": "Bristol Myers Squibb (BMY) concluded the recent trading session at $56.81, signifying a -0.58% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=49e307dfe05fcbb83356b8d0dc78f8fcc9555c06d5b5cde34e3955b5818ae231",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736462719,
      "headline": "Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade",
      "id": 132362378,
      "image": "https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb (BMY) concluded the recent trading session at $56.81, signifying a -0.58% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=49e307dfe05fcbb83356b8d0dc78f8fcc9555c06d5b5cde34e3955b5818ae231"
    }
  },
  {
    "ts": null,
    "headline": "How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It will report its Q4 2024 earnings on Feb. 6, 2025. Wall Street analysts expect the company to ...",
    "url": "https://finnhub.io/api/news?id=53801ec11bf49646360febc783f3063e9cdfc051be335072b04475a215f0a169",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736443814,
      "headline": "How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock",
      "id": 132353573,
      "image": "https://media.zenfs.com/en/benzinga_79/77b42950ad1b167b7c8c3602f457cd4f",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It will report its Q4 2024 earnings on Feb. 6, 2025. Wall Street analysts expect the company to ...",
      "url": "https://finnhub.io/api/news?id=53801ec11bf49646360febc783f3063e9cdfc051be335072b04475a215f0a169"
    }
  },
  {
    "ts": null,
    "headline": "J&J Pauses Sales of Atrial Fibrillation Device, Stock Down",
    "summary": "J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.",
    "url": "https://finnhub.io/api/news?id=dafcbc1711f31e1526350b7a6afdcf3e0fe9d2fe856f8c8baebde1ffe781afba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736429460,
      "headline": "J&J Pauses Sales of Atrial Fibrillation Device, Stock Down",
      "id": 132347873,
      "image": "https://media.zenfs.com/en/zacks.com/955c0f2ed0992898cedf76a9efa5b1f2",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.",
      "url": "https://finnhub.io/api/news?id=dafcbc1711f31e1526350b7a6afdcf3e0fe9d2fe856f8c8baebde1ffe781afba"
    }
  },
  {
    "ts": null,
    "headline": "Buy The Dip: SCHD's Top Holdings Show That It Is Way Too Cheap",
    "summary": "Discover why SCHD is a clear buy with a look at its top 10 holdings and why they make it an attractive investment opportunity right now.",
    "url": "https://finnhub.io/api/news?id=3b68bfa866454efa7af7ce3949bd40eddda968966891067ff52185ad91becf1d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736424000,
      "headline": "Buy The Dip: SCHD's Top Holdings Show That It Is Way Too Cheap",
      "id": 132349330,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289941019/image_1289941019.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover why SCHD is a clear buy with a look at its top 10 holdings and why they make it an attractive investment opportunity right now.",
      "url": "https://finnhub.io/api/news?id=3b68bfa866454efa7af7ce3949bd40eddda968966891067ff52185ad91becf1d"
    }
  },
  {
    "ts": null,
    "headline": "This Unpopular Dividend Stock Is a Buy",
    "summary": "Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position.  Specifically, the pharmaceutical giant's shares have declined by a disappointing 11.6% over the prior five years while the benchmark S&P 500 has delivered total returns of 97.5%, including dividends.  The company also continues to navigate generic competition for its cancer drug Revlimid, which it acquired as part of its 2019 deal for cancer specialist Celgene.",
    "url": "https://finnhub.io/api/news?id=611cecc0617d649a53a5762cd285b26ac28563c87ba7c011cb91d71c6f8d382f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736421300,
      "headline": "This Unpopular Dividend Stock Is a Buy",
      "id": 132353575,
      "image": "https://g.foolcdn.com/editorial/images/803307/high-yield-low-risk.jpg",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position.  Specifically, the pharmaceutical giant's shares have declined by a disappointing 11.6% over the prior five years while the benchmark S&P 500 has delivered total returns of 97.5%, including dividends.  The company also continues to navigate generic competition for its cancer drug Revlimid, which it acquired as part of its 2019 deal for cancer specialist Celgene.",
      "url": "https://finnhub.io/api/news?id=611cecc0617d649a53a5762cd285b26ac28563c87ba7c011cb91d71c6f8d382f"
    }
  },
  {
    "ts": null,
    "headline": "Buy 6 'Safer' Dividend Dogs Of 23 January Barron's Better Bets Than T-Bills",
    "summary": "Six of the top ten BBB Dogs are ideally priced, with dividends from $1K invested exceeding single share prices. Read more to see my picks.",
    "url": "https://finnhub.io/api/news?id=d20bcaa7ff495ceaaab28ed210083996d5a7bd34145d1296e18a40d15592d3e1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736404100,
      "headline": "Buy 6 'Safer' Dividend Dogs Of 23 January Barron's Better Bets Than T-Bills",
      "id": 132346430,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/512187837/image_512187837.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Six of the top ten BBB Dogs are ideally priced, with dividends from $1K invested exceeding single share prices. Read more to see my picks.",
      "url": "https://finnhub.io/api/news?id=d20bcaa7ff495ceaaab28ed210083996d5a7bd34145d1296e18a40d15592d3e1"
    }
  }
]